ArticleMedicine2025
Quercetin in the control and treatment of membranous nephropathy by regulating phosphatidylinositol 3-kinase/protein kinase-B signaling pathway.
Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Membranous nephropathy (MN) is an immune-mediated glomerular disease characterized by podocyte injury and immune complex deposition. The phosphatidylinositol 3-kinase/protein kinase-B (PI3K/protein kinase B [AKT]) pathway plays an important role in renal cell survival and inflammation. Quercetin (QUE), a natural flavonoid with antioxidant and anti-inflammatory properties, has shown potential renal protective effects. This study aimed to investigate the therapeutic effect of QUE on MN and its modulation of the PI3K/AKT signaling pathway. A cationic bovine serum albumin-induced MN rat model was established and divided into blank control, model control, and QUE groups. QUE (50 mg/kg/d) was administered orally for 10 weeks. Proteinuria, glomerular immunoglobulin G and complement 3 deposition, inflammatory cytokines, and PI3K/AKT pathway activity were examined. QUE treatment significantly reduced 24-h proteinuria compared with the model control group (P < .05). The intense granular deposition of immunoglobulin G and complement 3 observed in MN rats was notably alleviated after QUE administration. Furthermore, QUE downregulated the overexpression of PI3K and phosphorylated AKT proteins in renal tissue and improved the imbalance of serum inflammatory cytokines. QUE alleviated proteinuria, reduced immune complex deposition, and suppressed abnormal PI3K/AKT pathway activation in MN rats, suggesting that QUE confers renal protection through anti-inflammatory and signal-modulatory mechanisms.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.